Indivior Pharmaceuticals

INDV

Market cap $4.33B

The mean of analysts' price targets for Indivior Pharmaceuticals Inc. (INDV) points to a 32.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse risk, fewer infection-related complications, and reduced healthcare utilization among people living with opioid use disorder (OUD). “Collectively, these studies highlight the benefits of sustained treatment with monthly injectable buprenorphine, including reduced relapse risk and fewer serious complications that often drive acute care use,” said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. “These findings also emphasize the importance of proactively identifying patients at risk of treatment discontinuation and supporting continued access to evidence‑based medications for opioid use disorder.”

Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Indivior Pharmaceuticals Inc. (INDV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

RICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare Conference – New York, NY – June 3 rd Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 3rd and will also participate in a fireside chat on Wednesday, June 3rd at 11:05 a.m.

Medical stock Indivior is in a buy zone after first-quarter earnings. Indivior makes treatments for opioid addiction.

COCO, INDV and MPC stand out as momentum buys as investors apply Richard Driehaus' "buy high and sell higher" strategy.

Does Indivior Pharmaceuticals Inc. (INDV) have what it takes to be a top stock pick for momentum investors? Let's find out.

Indivior Pharmaceuticals Inc. (INDV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The mean of analysts' price targets for Indivior Pharmaceuticals Inc. (INDV) points to a 27.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.